Brauer Arnd B E, Kelly Geoff, Matthews Stephen J, Leatherbarrow Robin J
Department of Chemistry, Imperial College of Science, Technology and Medicine, South Kensington, London, SW7 2AY, U.K.
J Biomol Struct Dyn. 2002 Aug;20(1):59-70. doi: 10.1080/07391102.2002.10506822.
Bowman-Birk inhibitor (BBI) proteins contain an inhibitory motif comprising a disulfide-bonded sequence that interacts with serine proteinases. Recently, a small 14-residue peptide from sunflowers (SFTI-1), which has potent anti-trypsin activity, has been found to have the same motif. However, this peptide also has an unusual head-to-tail cyclisation. To address the role of the core inhibitory sequence itself, we have solved the (1)H-NMR solution structure of an antitryptic 11-residue cyclic peptide that corresponds to the core reactive site loops of both SFTI-1 and Bowman-Birk inhibitor proteins. A comparison is made between the secondary chemical shifts found in this family and the canonical regions of several other inhibitors, giving some insight into relative flexibility and hydrogen bonding patterns in these inhibitors. The solution structure of the core peptide in isolation is found to retain essentially the same three-dimensional arrangement of both backbone and side chains as observed in larger antitryptic BBI and SFTI-1 fragments as well as in the complete proteins. The retention of the canonical conformation in the core peptide explains the peptids inhibitory potency. It therefore represents a minimization of both the BBI and SFTI-1 sequences. We conclude that the core peptide is a conformationally defined, canonical scaffold, which can serve as a minimal platform for the engineering of biological activity.
鲍曼-伯克抑制剂(BBI)蛋白含有一个抑制基序,该基序由一个与丝氨酸蛋白酶相互作用的二硫键连接序列组成。最近,人们发现一种来自向日葵的14个残基的小肽(SFTI-1)具有强大的抗胰蛋白酶活性,并且具有相同的基序。然而,这种肽还具有不寻常的头尾环化结构。为了研究核心抑制序列本身的作用,我们解析了一种11个残基的抗胰蛋白酶环肽的(1)H-NMR溶液结构,该环肽对应于SFTI-1和鲍曼-伯克抑制剂蛋白的核心反应位点环。我们对该家族中发现的二级化学位移与其他几种抑制剂的典型区域进行了比较,从而对这些抑制剂的相对灵活性和氢键模式有了一些了解。发现分离出的核心肽的溶液结构在主链和侧链的三维排列上与在较大的抗胰蛋白酶BBI和SFTI-1片段以及完整蛋白质中观察到的基本相同。核心肽中典型构象的保留解释了该肽的抑制效力。因此,它代表了BBI和SFTI-1序列的最小化。我们得出结论,核心肽是一种构象明确的典型支架,可作为生物活性工程的最小平台。